Medtronic's Cardiac Resynchronization Therapy approved in Japan

By Lisa Kerner

Charlotte, N.C., July 7 - Medtronic, Inc. said its InSync III Marquis cardiac resynchronization therapy-defibrillator (CRT-D) has received approval, including reimbursement approval, by the Japanese Ministry of Health, Labor and Welfare.

The device will be available for sale in Japan Aug. 1.

The InSync III Marquis combines cardiac resynchronization and defibrillation therapies in a stopwatch-sized device for the treatment of moderate to severe heart failure in patients at risk for sudden cardiac arrest. In addition, the system includes Medtronic's Patient Alert feature, which notifies patients when follow-up care is needed.

Sudden cardiac arrest kills about 80,000 people in Japan annually, according to Medtronic.

Medtronic is a Minneapolis-based medical device company.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.